Literature DB >> 3337928

What are the 'best' measurements for monitoring patients during short-term second-line therapy?

J S Dixon1, S Hayes, P D Constable, H A Bird.   

Abstract

Seventy-one patients with active rheumatoid arthritis were treated with one of five second-line agents and monitored for 24 weeks using seven clinical and seven laboratory measurements. Statistical tests were used to determine which measures changed fastest, which changed most and which most closely reflected changes in the others. The results consistently showed that articular index and summated change score were the 'best' clinical measures while ESR and plasma viscosity were the 'best' laboratory measures. Traditional measures such as grip strength and joint size fared badly and cannot be recommended. Clinical variables improved slightly more rapidly than laboratory measures, but the latter showed the greater change.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337928     DOI: 10.1093/rheumatology/27.1.37

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  5 in total

1.  Response criteria for slow acting antirheumatic drugs.

Authors: 
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

Review 2.  What should we hope to achieve when treating rheumatoid arthritis?

Authors:  D L Scott; T D Spector; T Pullar; B McConkey
Journal:  Ann Rheum Dis       Date:  1989-03       Impact factor: 19.103

3.  Can we develop simple response criteria for slow acting antirheumatic drugs?

Authors:  D L Scott; J E Dacre; A Greenwood; L Treasure; E C Huskisson
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

4.  How reliable is ESR as a measure of disease activity in rheumatoid arthritis treated with hydroxychloroquine?

Authors:  J S Dixon; M Greenwood; H A Bird
Journal:  Clin Rheumatol       Date:  1988-06       Impact factor: 2.980

5.  Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.

Authors:  Michael M Ward; Lori C Guthrie; Maria I Alba
Journal:  Ann Rheum Dis       Date:  2014-05-01       Impact factor: 19.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.